GlassScriptPhysician profile
Teresa Yates
NPI 1033119391
$6,771.72
in general payments reported to CMS, 2019-2025
20 companies · $1,793 in 2025
The $1,793 reported for 2025 was more than what 93% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $152 · 2022: $2,171 · 2023: $1,975 · 2024: $682 · 2025: $1,793.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,668 · Travel and Lodging: $1,782.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,667.54 |
| Travel and Lodging | $1,781.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $4,069.84 | 2022-2025 | Mitraclip, Navitor, Triclip |
| Edwards Lifesciences Corporation | $1,161.11 | 2022-2025 | Pascal |
| Boston Scientific Corporation | $360.16 | 2021-2025 | Watchman Flx, Watchman, Watchman Access System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $267.35 | 2021-2025 | Jardiance |
| Cvrx, INC. | $165.98 | 2025 | Barostim Neo System |
| Janssen Pharmaceuticals, INC | $118.57 | 2022-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $113.72 | 2023-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $84.27 | 2021-2024 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $67.22 | 2024-2025 | Eliquis, Camzyos |
| Novartis Pharmaceuticals Corporation | $61.84 | 2022-2023 | |
| Kestra Medical Technology Services, INC. | $60.46 | 2024 | Assure Wcd |
| Pfizer INC. | $47.11 | 2024 | |
| Alnylam Pharmaceuticals INC. | $43.93 | 2024-2025 | Amvuttra |
| Philips North America LLC | $35.10 | 2022-2025 | Mcot |
| Amgen INC. | $28.22 | 2022-2023 | Repatha |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $18.70 | 2023 | Injectafer |
| Abiomed | $18.42 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $17.77 | 2024 | |
| Sanofi-Aventis U.S. LLC | $17.20 | 2022 | |
| Amarin Pharma, INC. | $14.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Teresa Yates listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.